BRIEF-SITE Centers Sells Winter Garden Village For About $165 Million In Cash- SEC Filing-February 2024-www.financetom.com

BRIEF-SITE Centers Sells Winter Garden Village For About $165 Million In Cash- SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-SITE Centers Sells Winter Garden Village For About $165 Million In Cash- SEC Filing

Jun 23, 2025 1:56 PM

June 23 (Reuters) - Site Centers Corp ( SITC ):

* SITE CENTERS CORP ( SITC ) - UNIT, DDR WINTER GARDEN, ENTERS

PURCHASE

AGREEMENT WITH RA2 WINTER GARDENS VILLAGE - SEC FILING

* SITE CENTERS CORP ( SITC ) - SELLS WINTER GARDEN VILLAGE FOR ABOUT

$165

MILLION IN CASH- SEC FILING

Source text:

Further company coverage:

Previous page： Sector Update: Consumer Stocks Mixed Premarket Wednesday Next page： Organon Says US FDA Accepts Biologic License Application for Proposed Denosumab Biosimilar HLX14

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Sector Update: Consumer Stocks Mixed Premarket Wednesday

Oct 30, 2024

09:18 AM EDT, 10/30/2024 (MT Newswires) -- Consumer stocks were mixed premarket Wednesday, with The Consumer Staples Select Sector SPDR Fund ( XLP ) slightly lower and The Consumer Discretionary Select Sector SPDR Fund ( XLY ) up 0.3%. Brinker International ( EAT ) shares were up over 7% after the company reported higher fiscal Q1 adjusted earnings and revenue...

Organon Says US FDA Accepts Biologic License Application for Proposed Denosumab Biosimilar HLX14

Oct 30, 2024

10:57 AM EDT, 10/30/2024 (MT Newswires) -- Organon (OGN) and Shanghai Henlius Biotech said Wednesday that the US Food and Drug Administration has accepted the biologic license application for HLX14, an investigational biosimilar of denosumab. Denosumab is approved in several countries for different indications including the treatment of osteoporosis in postmenopausal women, the companies said. Organon secured the exclusive commercialization...

Bunge Beats On Q3 Earnings, Agribusiness Weighs On Growth Amid Global Margin Pressure

Oct 30, 2024

Bunge Limited reports strong Q3 earnings of $2.29 per share, exceeding expectations. Results declined from the prior year due to the current global margin environment.Bunge Limited reported third-quarter adjusted earnings per share of $2.29, beating the street view of $2.14. Quarterly sales of $12.908 billion outpaced the analyst consensus estimate of $12.774 billion. Bunge Global ( BG ) said it...

bioAffinity Technologies Secures Japanese Patent for Lung Cancer Diagnostic Method

Oct 30, 2024

10:42 AM EDT, 10/30/2024 (MT Newswires) -- bioAffinity Technologies (BIAF) said Wednesday it received a Japanese patent for its CyPath Lung diagnostic test method, which predicts lung cancer risk. The patent expands bioAffinity's portfolio to 17 granted patents, the company said. Shares of bioAffinity rose 2.7% in recent trading. Price: 1.34, Change: +0.03, Percent Change: +2.69 ...